Results

Total Results: 1,147 records

Showing results for "event".

161. Screening for Coronary Heart Disease: Clinician Fact Sheet (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/cAs__BR8J4rgcZ4vQgfaTx
     April 01, 2009 - Reasons to consider screening in an individual patient: y A family history of early CHD (CHD event

162. Evidence Summary: Primary Open-Angle Glaucoma: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/primary-open-angle-glaucoma-screening
     May 24, 2022 - 0.71-19.32]; I 2 = 0%) (eFigure 8 in the JAMA Supplement), 21 , 37 , 41 , 90 , 106 or any adverse event … 4.03]; I 2 = 82%). 41 , 76 , 77 However, estimates were imprecise and the estimate for any adverse event … The LiGHT trial found no differences between SLT and medical therapy in likelihood of any adverse event … to 2.07), withdrawal due to adverse events (3 trials, n = 1875; RRs, 4.73 to 38.20), and any adverse event … found no differences between SLT vs medical therapy in risk of serious adverse events or any adverse event

163. Evidence Summary: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/statin-use-in-adults-preventive-medication
     August 23, 2022 - prevention in adults aged 40 to 75 years with at least 1 CVD risk factor and a calculated 10-year CVD event … stopped after 2 to 3 years because of interim analyses indicating statin benefits 27 , 29 or low CVD event … AE indicates adverse event … White: 96 Other race or ethnicity: NR LDL-C: 157 HDL-C: 39 TC: 224 Triglycerides: 120 Prior CVD event … settings Most trials evaluated moderate-intensity statin therapy Abbreviations: AE, adverse event

164. Draft Recommendation: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/vitamin-supplementation-to-prevent-cvd-and-cancer-preventive-medication
     May 04, 2021 - =107,772) after 3 to 10 years of followup or on the composite outcome of any cardiovascular disease event … 0.96 [95% CI, 0.86 to 1.07]; 7 trials; n=74,617), the composite outcome of any cardiovascular disease event … Event rates for cardiovascular disease mortality and cardiovascular disease events were too low to draw

165. Recommendation: Obstructive Sleep Apnea in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/obstructive-sleep-apnea-in-adults-screening
     November 15, 2022 - Share to Facebook Share to X Share to WhatsApp Share to Email Print Final Recommendation Statement Obstructive Sleep Apnea in Adults: Screening November 15, 2022 Recommendations made by the USPSTF are independent of the U.S. government. They…

166. Archived: Diabetes Mellitus (Type 2) in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/diabetes-mellitus-type-2-in-adults-screening
     June 15, 2008 - stroke, and revascularization) from 25% to 20%; that is, using simvastatin prevents 1 major vascular event

167. Archived: Diabetes Mellitus (Type 2) in Adults: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/diabetes-mellitus-type-2-in-adults-screening-2008
     June 15, 2008 - stroke, and revascularization) from 25% to 20%; that is, using simvastatin prevents 1 major vascular event

168. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
     September 03, 2019 - Estimates used combined RRs from the meta-analyses and combined event rates from placebo groups of included … Combined event rates were determined from a meta- analysis of placebo event rates from each trial by … 95% CIs were estimated using a simulation method that assumed that the logs of both the RRs and the event … c Intended treatment duration is 5 years or until a breast, neoplastic, cardiovascular, or toxicity event … Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women

169. USPSTF Clinician Summary of USPSTF Recommendation: Screening for Lipid Disorders in Children and Adolescents (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/SkbkgyTc826aqUmKghKELw
     July 01, 2023 - USPSTF Clinician Summary of USPSTF Recommendation: Screening for Lipid Disorders in Children and Adolescents USPSTF Clinician Summary of USPSTF Recommendation Screening for Lipid Disorders in Children and Adolescents July 2023 What does the USPSTF recommend? …

170. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/mk-eb9VtB_jx885wnjuzk3
     January 01, 2024 - For example, in the JUPITER trial, the NNT to prevent 1 cardiovascular event was 94 in people younger

171. Draft Recommendation: Anxiety in Children and Adolescents: Screening | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/screening-anxiety-children-adolescents
     April 12, 2022 - in progress Draft Recommendation Statement Anxiety in Children and Adolescents: Screening April 12, 2022 Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Dep…

172. Archived: Evidence Summary: Diabetes Mellitus (Type 2) in Adults: Screening, 2003 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/diabetes-mellitus-type-2-in-adults-screening-2003
     February 03, 2003 - After 10 years, more than 20% of such persons will have had a major cardiovascular event (for example … considers the number needed to screen (NNS) to prevent one case of blindness in one eye or one CVD event … If one screened only people with hypertension for diabetes, estimates of the NNS to prevent one CVD event … With less favorable assumptions, the NNS calculations for preventing one CVD event are still lower than … same as relative risk reduction for photocoagulation. 10 ‡ Assumptions: 7.5% 5-year risk for CVD event

173. Evidence Summary: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
     April 17, 2018 - alone compared with placebo, 1 RCT reported no cardiovascular disease events in the placebo group, 1 event … review were not powered for the fracture or harm outcomes considered; thus, small sample sizes and low event … outcome ascertainment, some relying on self-report to identify cases and others relying on adverse event … rare; no participants in the control group had any events, 1 participant in the 600-mg group had an event … , and 2 participants in the 1200-mg group had an event. 22 Return to Table of Contents

174. Screening for Type 2 Diabetes Mellitus in Adults: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/36geybKjEXsHDoPkRR5KVZ
     June 01, 2008 - stroke, and revascu- larization) from 25% to 20%; that is, using simvastatin prevents 1 major vascular event

175. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary27/breast-cancer-medications-for-risk-reduction-2013
     April 15, 2013 - Thromboembolic event incidence was increased for tamoxifen (RR, 1.93 [CI, 1.41 to 2.64]; 4 trials; 4 … Coronary heart disease event or stroke incidence was not increased in placebo-controlled trials 7 , 8 … Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women … † 67% **   84.5% (109/129) ‡‡ 89.2% 87.4% Discontinuation due to protocol specified event … 0.7% (1/143) NR NR NR NR NR NR NR Discontinuation due to non–protocol-specified event

176. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication
     April 26, 2022 - It is important to note that increasing age heavily influences the ACC/AHA estimated 10-year CVD event … have initiated aspirin use, the net benefits continue to accrue over time in the absence of a bleeding event

177. Archived: Evidence Summary: High Blood Pressure in Adults, Children, and Adolescents: Screening, 2003 | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/high-blood-pressure-adults-children-adolescents-screening-2003
     April 01, 2003 - numbers needed to treat (NNT) over 5 years ranged from 200 to 400 to prevent 1 congestive heart failure event … ranged from approximately 900 to prevent 1 stroke to 10,000 to prevent 1 case of coronary heart disease event … The number needed to treat over 5 years to prevent 1 cardiovascular event was 18 (95% CI 17 to 19) in

178. Kbjjfcap9Xvhkp43U-7B9Q (pdf file)
     www.uspreventiveservicestaskforce.org/home/getfilebytoken/KbJjfcaP9XvhkP43u-7b9q
     July 01, 2014 - serious adverse events (12 trials; RR, 0.8 [CI, 0.6 to 1.1]; I2 � 0%) (22, 24, 39–47, 58) or any adverse event … Rates of withdrawal due to adverse events ranged from 0% to 24% with antiviral therapy, with only 1 event … ]; I2 � 0%), withdrawals due to adverse events (RR, 7.6 [CI, 1.1 to 52]; I2 � 38%), and any adverse event

179. Procedure Manual Appendix XII. Summary of Evidence Table for Evidence Reviews | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/procedure-manual/procedure-manual-appendix-xii-summary-evidence-table-evidence-reviews
     July 01, 2017 - are close and confidence intervals are narrow, without concerns about insufficient sample size, low event

180. Procedure Manual Appendix XII. Summary of Evidence Table for Evidence Reviews | United States Preventive Services Taskforce
     www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-appendix-xii-summary-evidence-table-evidence-reviews
     July 01, 2017 - are close and confidence intervals are narrow, without concerns about insufficient sample size, low event